Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857856 | 0.81 | HRH3 (0.52) | HRH3MGLLCHRM4 | |
| SCHEMBL3859926 | 0.80 | HRH3 (0.61) | HRH3IRAK4KCNH2 | |
| Hydrochloric Acid SCHEMBL3862015 | 0.80 | HRH3 (0.51) | HRH3MGLLCHRM4 | |
| SCHEMBL3858253 | 0.79 | HRH3 (0.46) | HRH3IRAK4CHRM4 | |
| SCHEMBL3865348 | 0.78 | HRH3 (0.58) | HRH3IRAK4MGLLKCNH2 | |
| SCHEMBL30462894 | 0.78 | HRH3 (0.52) | HRH3KCNH2 | |
| SCHEMBL4689478 | 0.78 | HRH3 (0.41) | HRH3IRAK4CHRM4KCNH2 | |
| SCHEMBL3861953 | 0.77 | HRH3 (0.57) | HRH3IRAK4KCNH2 | |
| Hydrochloric Acid SCHEMBL3861516 | 0.77 | HRH3 (0.57) | HRH3IRAK4MGLLKCNH2 | |
| SCHEMBL3863873 | 0.77 | CHRM4 (0.44) | HRH3CHRM4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | claimed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | claimed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | claimed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | claimed |
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | HRH3 1322/4885IRAK4 2812/4885ATR 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.